RORA and prostate carcinoma: Therefore, we investigated a specific cross-regulation between RORα1, not by RORα4, and Wnt/β-catenin signaling in a prostate cancer cell culture model, a RORα-deficient mouse model, and in clinical samples of patients with prostate carcinomas.